Medication

Insulin (Humalog/NovoLog)

Half-life

~1 hour

What is Insulin (Humalog/NovoLog)?

Rapid-acting insulin analogs (lispro/aspart) for meal-time glucose control.

Fast insulin receptor agonism post-prandially increases peripheral glucose disposal and suppresses hepatic glucose production.

~1 hour (plasma); action ~3-5 hours

with IGF-1 LR3
Avoid · severe
Both IGF-1 LR3 and insulin lower blood glucose through distinct pathways. Combined use carries serious risk of fatal hypoglycemia. This combination is used only in advanced clinical or elite bodybuilding contexts with full medical support.
Timing: Never combine without continuous glucose monitoring and medical supervision
with CJC-1295
Caution · moderate
GH peptides elevate fasting glucose and may interfere with insulin sensitivity; close glucose monitoring required when stacking.
Timing: Separate dosing windows by 2+ hours
with Growth Hormone
Caution · severe
GH induces insulin resistance; combining with exogenous insulin creates complex glucose management requirements. Life-threatening hypoglycemia risk if dosing is incorrect.
Timing: Never combine without medical supervision and continuous glucose monitoring
with Ipamorelin
Caution · moderate
GHRPs blunt insulin sensitivity acutely. If both are part of a protocol, separate by 90+ min and monitor glucose carefully.
Timing: Do not co-administer in the same window
with Semaglutide
Caution · severe
Both semaglutide and insulin lower blood glucose. Combining them without precise medical dosing guidance carries serious hypoglycemia risk. This combination requires a treating endocrinologist — not for unsupervised use.
Timing: Never combine without continuous glucose monitoring and medical supervision

Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.